Company Description
Resonate Blends, Inc. (now Apollo Biowellness, Inc.) (OTC Pink: KOAN) is described in recent company communications as a business engaged in the discovery, development and marketing of products designed to better mankind. Under the name Apollo Biowellness, Inc., and together with its subsidiary Evolutionary Biologics, Inc., the company focuses on biologic-based products within the field of regenerative medicine as defined by the National Institutes of Health. According to multiple press releases, intended products are to be marketed under third-party label exemptions and are aimed at both consumer and professional markets.
Company disclosures state that Apollo Biowellness is concentrating its current efforts on licensed, patent-pending natural stem cell mobilizing agents. These agents are described as capable of enhancing an individual's ability to mobilize their own adult stem cells from bone marrow. The company also reports that it is licensed under a patent-pending application to market a dual-acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. These product concepts form a core part of the company’s stated regenerative and wellness strategy.
Corporate evolution and name history
In recent news releases, the company is identified as Apollo Biowellness, Inc., f/k/a Resonate Blends, Inc., indicating that Resonate Blends, Inc. has transitioned to operating under the Apollo Biowellness name while retaining the KOAN ticker on the OTC Pink market. The company’s communications emphasize that Apollo Biowellness and Evolutionary Biologics are working together in regenerative medicine using biologic-based products, with a focus on both professional medical channels and consumer-oriented offerings.
Regenerative medicine and biologic-based focus
Across its announcements, Apollo Biowellness highlights a focus on regenerative medicine using biologic-based products. The company describes itself as positioning to use biologic materials and natural agents in areas such as stem cell mobilization, diet support, and aesthetic or wellness applications. It has repeatedly referenced biologic products associated with Evolutionary Biologics, including exosome and placental-based products described in its communications.
In an October 2024 press release, the company outlined that Evolutionary Biologics' biologics are produced in an ISO5 GMP-certified FDA laboratory and are distributed through a network of medical professionals. The same communication notes that Evolutionary Biologics plans to introduce PRP and PRF products to complement its existing portfolio, which are intended to support aesthetic and surgical procedures in clinical settings.
Evolutionary Biologics and aesthetic/regenerative channels
Evolutionary Biologics, Inc., the company’s subsidiary, is presented as a key operating division. Company statements describe Evolutionary Biologics as offering biologic products for aesthetic and regenerative health markets, with distribution through Plastic Surgeons, Dermatologists, Medical Spas and other medical professionals. The "Evo Bio" brand is referenced as a core brand for Med Spas, injectors, plastic surgeons and related practitioners.
In several press releases, Apollo Biowellness reports entering into distribution and collaboration agreements for Evolutionary Biologics products. These include an exclusive distribution sales agreement with Revive Regenerative, Inc. for the United States and Canada, and a joint venture and distribution partnership with Reveal Lasers LLC to expand the reach of Evolutionary Biologics’ biologic products across aesthetic and regenerative health markets. These arrangements are described as allowing Evolutionary Biologics to focus on development of additional products and brands while partners handle sales and distribution.
Consumer and cosmetic product initiatives
Company communications outline plans for shelf-stable biologic cosmetic products. Apollo Biowellness has described a consumer shelf-stabilized biologic cosmetic brand that does not require refrigeration, in contrast to certain existing products. In later announcements, the company introduced a new brand called Cielo Skin Care, characterized as a line of consumer products using self-stabilized exosome and placental-based products with human tissue as a core ingredient. The company states that these molecules are intended to maximize the regeneration and regrowth of skin cells, with an emphasis on anti-aging effects related to aging, sun exposure and other skin damage.
According to the company’s description, the Cielo Skin Care line is planned for launch through multiple channels, including major retail, e-commerce, direct-to-consumer marketing, social media influencers and TV shopping outlets. These statements indicate a focus on consumer-facing biologic cosmetic products alongside the professional Evo Bio brand.
Pet and veterinary biologic concepts
In its corporate updates, Apollo Biowellness also describes plans for a pet and veterinarian biologic product using exosomes and placental products for pets. The company has stated that this Doctor-branded product is intended to be sold through licensed veterinarians, clinicians and pet professionals. The product concept, as described by the company, is based on natural biologic products to address issues such as arthritis, joint problems, inflammation and skin conditions in pets, with topical and injectable therapeutics mentioned in its communications.
Geographic and market reach as described by the company
Press releases indicate that Apollo Biowellness is based in North Bergen, New Jersey. The company has also described distribution relationships and discussions that involve markets in the United States and Canada, as well as Europe, the Middle East, Asia, South America and Latin America through various partners. These references appear in the context of distribution agreements and negotiations for Evolutionary Biologics products and future biologic offerings.
Business model as stated in company communications
Across multiple announcements, Apollo Biowellness describes a model centered on research and development, production and manufacturing, and wholesale distribution of biologic products. The company has stated that it aims to focus on product creation, development, manufacturing, intellectual property and standard operating procedures, while relying on distribution partners and aesthetic companies to manage sales and marketing. This approach is described as applying to both professional medical channels and consumer markets.
Risk and usage guidance
In its press releases, Apollo Biowellness includes a recurring advisory that before using any of its products, individuals should consult with their veterinarian and/or family doctor. This language appears alongside descriptions of both human and pet-focused biologic products and reflects the company’s own stated guidance regarding product use.
Frequently Asked Questions (FAQ)
- What does Resonate Blends, Inc. (Apollo Biowellness, Inc.) say it does?
According to its press releases, Apollo Biowellness, Inc., formerly known as Resonate Blends, Inc., is engaged in the discovery, development and marketing of biologic-based products in regenerative medicine, with offerings intended for both consumer and professional markets. - How does the company describe its focus in regenerative medicine?
The company states that it is positioning itself in the field of regenerative medicine as defined by the National Institutes of Health, using biologic-based products, including licensed, patent-pending natural stem cell mobilizing agents and other biologic formulations. - What are Evolutionary Biologics and the Evo Bio brand?
Evolutionary Biologics, Inc. is identified as a subsidiary of Apollo Biowellness. Company communications describe the Evo Bio brand as a line of biologic products for Med Spas, injectors, plastic surgeons and similar professionals, with distribution through medical and aesthetic channels. - What is Cielo Skin Care as described by the company?
Cielo Skin Care is described in a company press release as a new brand of consumer products using self-stabilized exosome and placental-based products with human tissue as a core ingredient, intended to support skin cell regeneration and anti-aging effects. - How does Apollo Biowellness say it plans to bring products to market?
The company’s announcements reference marketing under third-party label exemptions, distribution through partners such as Revive Regenerative, Inc. and Reveal Lasers LLC, and consumer channels including retail, e-commerce, direct-to-consumer marketing, social media influencers and TV shopping outlets. - Does the company mention products for pets?
Yes. In its corporate updates, Apollo Biowellness describes plans for a pet and veterinarian biologic product using exosomes and placental products, intended for issues such as arthritis, joint problems, inflammation and skin conditions in pets, to be sold through licensed veterinarians and pet professionals. - What guidance does the company provide about using its products?
In multiple press releases, the company advises that before using any of its products, individuals should consult with their veterinarian and/or family doctor. - Is KOAN still associated with Resonate Blends, Inc.?
Recent press releases refer to the issuer as Apollo Biowellness, Inc., formerly known as Resonate Blends, Inc., and use the KOAN ticker on the OTC Pink market, indicating that the KOAN symbol is associated with the renamed entity.
Stock Performance
Resonate Blends (KOAN) stock last traded at $0.0016, up 6.67% from the previous close. Over the past 12 months, the stock has gained 100.0%. At a market capitalization of $409.7K, KOAN is classified as a micro-cap stock with approximately 256.0M shares outstanding.
Latest News
Resonate Blends has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 4 with negative movement. Key topics include management, partnership. View all KOAN news →
SEC Filings
Financial Highlights
Resonate Blends generated $1.9M in revenue over the trailing twelve months, retaining a 65.2% gross margin, operating income reached -$1.7M (-89.5% operating margin), and net income was -$2.1M, reflecting a -112.5% net profit margin. Diluted earnings per share stood at $-0.02. The company generated -$1.0M in operating cash flow. With a current ratio of 0.20, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Resonate Blends (KOAN) currently stands at 690.2 thousand shares, up 1000.0% from the previous reporting period, representing 0.3% of the float. Over the past 12 months, short interest has increased by 1213.9%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Resonate Blends (KOAN) currently stands at 1.0 days, up Infinity% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 0.0 to 1.0 days.
KOAN Company Profile & Sector Positioning
Resonate Blends (KOAN) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing KOAN often look at related companies in the same sector, including Cbd Life Science (CBDL), Ovation (OVATF), 4Cable Tv Intern (CATV), Hemp (HEMP), and Panacea Life Sciences Hldgs Inc (PLSH). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate KOAN's relative position within its industry.